ChiCTR2500108319 版本V1.0 版本创建时间2025/08/28 11:06:51 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500108319 

最近更新日期:

Date of Last Refreshed on:

2025-08-28 11:06:37 

注册时间:

Date of Registration:

2025-08-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于Logistic回归和随机森林的头颈癌患者衰弱风险预测模型的构建与验证

Public title:

Construction and validation of the frailty risk prediction in patients with head and neck cancer based on random forest algorithm and logistic regressionh

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于Logistic回归和随机森林的头颈癌患者衰弱风险预测模型的构建与验证

Scientific title:

Construction and validation of the frailty risk prediction in patients with head and neck cancer based on random forest algorithm and logistic regressionh

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

舒玲 

研究负责人:

舒玲 

Applicant:

Shu Ling 

Study leader:

Shu Ling 

申请注册联系人电话:

Applicant telephone:

+86 136 7731 2900

研究负责人电话:

Study leader's
telephone:

+86 136 7731 2900

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

191293505@qq.com

研究负责人电子邮件:

Study leader's E-mail:

191293505@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市雨花区韶山南路161号

研究负责人通讯地址:

湖南省长沙市雨花区韶山南路161号

Applicant address:

No. 161, Shaoshan South Road, Yuhua District, Changsha City, Hunan Province

Study leader's address:

No. 161, Shaoshan South Road, Yuhua District, Changsha City, Hunan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

长沙市中心医院(南华大学附属长沙中心医院)

Applicant's institution:

Changsha Central Hospital (Changsha Central Hospital Affiliated to the University of South China)

研究负责人所在单位:

长沙市中心医院(南华大学附属长沙中心医院)

Affiliation of the Leader:

Changsha Central Hospital (Changsha Central Hospital Affiliated to the University of South China)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025医审第068号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

长沙市中心医院医学伦理分委员会

Name of the ethic committee:

Medical Ethics Subcommittee of Changsha Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-16 00:00:00

伦理委员会联系人:

王智芳

Contact Name of the ethic committee:

Wang Zhifang

伦理委员会联系地址:

湖南省长沙市雨花区韶山南路161号

Contact Address of the ethic committee:

No. 161, Shaoshan South Road, Yuhua District, Changsha City, Hunan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 731 8566 7845

伦理委员会联系人邮箱:

Contact email of the ethic committee:

csszxyyll@163.com

研究实施负责(组长)单位:

长沙市中心医院(南华大学附属长沙中心医院)

Primary sponsor:

Changsha Central Hospital (Changsha Central Hospital Affiliated to the University of South China)

研究实施负责(组长)单位地址:

湖南省长沙市雨花区韶山南路161号

Primary sponsor's address:

No. 161, Shaoshan South Road, Yuhua District, Changsha City, Hunan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南省

市(区县):

长沙市

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

长沙市中心医院(南华大学附属长沙中心医院)

具体地址:

湖南省长沙市雨花区韶山南路161号

Institution
hospital:

Changsha Central Hospital/the Affiliated Changsha Central Hospital,University of South China

Address:

No. 161, Shaoshan South Road, Yuhua District, Changsha City, Hunan Province

经费或物资来源:

湖南省自然科学基金

Source(s) of funding:

Natural Science Foundation of Hunan Province of China

研究疾病:

头颈癌  

Target disease:

Head and neck cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

构建头颈癌患者衰弱的预测模型,用以预测头颈癌患者发生衰弱的风险。  

Objectives of Study:

T1. Aged ≥ 18 years. 2. Diagnosed with head and neck cancer through pathological or other diagnostic methods (including laryngeal cancer, hypopharyngeal cancer, submandibular gland cancer, tonsillar cancer, parotid gland cancer, salivary gland cancer, tongue cancer, gingival cancer, oropharyngeal cancer, lip/oral cavity cancer, nasopharyngeal cancer, thyroid cancer, etc.). 3. Fully conscious, with the patient demonstrating awareness of their own medical condition. 4. Capable of reading and understanding written text, without cognitive impairments. o develop a predictive model for frailty in head and neck cancer patients, to assess the risk of frailty in this population.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄>=18岁; 2.经病理学等方法明确诊断为头颈癌(包括喉癌、下咽癌、颌下腺癌、扁桃体癌、腮腺癌、唾液腺癌、舌癌、牙龈癌、口咽癌、唇/口腔癌、鼻咽癌、甲状腺癌等); 3.意识清楚,患者明确自身患病情况; 4.对文字有阅读能力且无理解障碍。

Inclusion criteria

1. Age>=18 years old; 2. Clearly diagnosed as head and neck cancer by pathology and other methods (including laryngeal cancer, hypopharyngeal cancer, submandibular adenocarcinoma, tonsil cancer, parotid gland cancer, salivary gland cancer, tongue cancer, gum cancer, oropharyngeal cancer, lip/oral cancer, nasopharyngeal cancer, thyroid cancer, etc.); 3. Clear consciousness, the patient knows his own illness; 4. Have the ability to read words and have no comprehension barriers.

排除标准:

1.患有其他部位恶性肿瘤及复发者; 2.严重的心肝肺功能不全或患有重度免疫系统疾病; 3.有严重认知功能障碍或精神疾病患者。

Exclusion criteria:

1. Those with malignant tumors and recurrence in other parts; 2. Severe cardiovascular and liver pulmonary insufficiency or severe immune system disease; 3. Patients with severe cognitive dysfunction or mental illness.

研究实施时间:

Study execute time:

From 2025-07-01 00:00:00 To 2027-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-08-30 00:00:00 To 2027-06-30 00:00:00

干预措施:

Interventions:

组别:

头颈癌衰弱患者观察组

样本量:

368

Group:

Observation group of frail patients with head and neck cancer

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南省 

市(区县):

长沙市 

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

长沙市中心医院(南华大学附属长沙中心医院) 

单位级别:

三甲 

Institution
hospital:

Changsha Central Hospital/the Affiliated Changsha Central Hospital,University of South China

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

衰弱表型量表评分

指标类型:

主要指标

Outcome:

Phenotype Frailty score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

安德森症状评估量表-头颈部模块评分

指标类型:

次要指标

Outcome:

M.D.Anderson Symptom Inventory-Head&Neck score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

营养风险筛查量表评分

指标类型:

次要指标

Outcome:

Nutrition Risk Screening 2002 score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

医院焦虑抑郁量表评分

指标类型:

次要指标

Outcome:

Hospital Anxiety and Depression Scale score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

癌因性疲乏量表评分

指标类型:

次要指标

Outcome:

Cancer-Related Fatigue Scale Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体意象量表评分

指标类型:

次要指标

Outcome:

Body Image Scale Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

None

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-08-28 11:06:37